2. Signaling Pathways
  3. GPCR/G Protein
  4. GCGR
  5. GCGR Antagonist

GCGR Antagonist

GCGR Antagonists (31):

Cat. No. Product Name Effect Purity
  • HY-P1143
    [Des-His1,Glu9]-Glucagon amide
    		Antagonist
    [Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes.
  • HY-107129
    MK-3577
    		Antagonist
    MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research.
  • HY-19374
    BAY-27-9955
    		Antagonist
    BAY-27-9955 is an orally active non-peptide glucagon receptor antagonist. Bay 27-9955 competitively blocks the interaction of glucagon with the human glucagonreceptor at an IC50 value of 110 nM. BAY-27-9955 can be used for the study of type 2 diabetes.
  • HY-P1543
    Exendin-3
    		Antagonist 98.31%
    Exendin-3 is a biologically active peptides isolated from venoms of the Gila monster lizards, Heloderma horridurn.
  • HY-128103
    Glucagon receptor antagonist-7
    		Antagonist
    Glucagon receptor antagonist-7 (Compound 1) is an antagonist for hGCGR, that inhibits the binding of 125I-labeled glucagon to the human glucagon receptor (hGCGR) with IC50 of 181 nM. Glucagon receptor antagonist-7 activates glucagon-stimulated adenylyl cyclase with a KDB of 81 nM in CHO cell. Glucagon receptor antagonist-7 inhibits glucagon-mediated glycogenolysis in human hepatocytes, and lowers blood glucose levels.
  • HY-145632A
    Pemvidutide TFA
    		Antagonist
    Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research.
  • HY-169707
    GCGR antagonist 3
    		Antagonist
    GCGR antagonist 3 (example 1) is an antagonist of the glucagon receptor (GCGR) and can be used in diabetes research.
  • HY-P3608
    [Des-His1,Glu9] Glucagon
    		Antagonist
    [Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes.
  • HY-P0211
    [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)
    		Antagonist
    [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human), a growth hormone releasing factor (GRF) analogue, is a vasoactive intestinal peptide (VIP) antagonist.
  • HY-12735
    SCH 900822
    		Antagonist
    SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes.
  • HY-12525A
    LGD-6972 sodium
    		Antagonist
    LGD-6972 sodium is a selective and orally active glucagon receptor antagonist. LGD-6972 sodium has the potential for type 2 diabetes research.